US2019001025A1PendingUtilityA1

Biodegradable scaffolds

58
Assignee: UNIV TEXASPriority: Jul 9, 2010Filed: Aug 27, 2018Published: Jan 3, 2019
Est. expiryJul 9, 2030(~3.9 yrs left)· nominal 20-yr term from priority
Inventors:Mauro FerrariRachel BuchananChristine SmidEnnio Tasciotti
A61L 27/3847A61L 27/56A61L 27/20A61L 2300/252A61L 27/3834A61L 27/58A61L 2430/02A61L 27/18A61L 2300/64A61L 27/54A61L 2300/41A61L 27/446A61L 2300/406A61L 2300/44A61L 27/16
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

In some embodiments, the present invention provides compositions that comprise: (1) a biodegradable polymer matrix; and (2) at least one biodegradable reinforcing particle that is dispersed in the matrix. In some embodiments, the biodegradable reinforcing particle is selected from the group consisting of porous oxide particles and porous semiconductor particles. In additional embodiments, the compositions of the present invention further comprise a (3) porogen particle that is also dispersed in the matrix. In further embodiments, the compositions of the present invention are also associated with one or more active agents. In various embodiments, the active agents are associated with the biodegradable polymer matrix, the biodegradable reinforcing particle, and/or the porogen particle. In various embodiments, the compositions of the present invention may be utilized as scaffolds, such as scaffolds for treating bone defects. Further embodiments of the present invention pertain to methods of making the compositions of the present invention.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of making a drug delivery composition, comprising dispersing in a biodegradable polymer matrix (a) at least one biodegradable reinforcing particle selected from the group consisting of porous oxide particles and porous semiconductor particles; and (b) a population of hydrogel porogen particles that comprises at least one active agent. 
     
     
         2 . The method of  claim 1 , wherein the at least one active agent is selected from the group consisting of therapeutics, imaging agents, anti-inflammatory agents, antibiotics, proteins, platelet rich plasma, cells, degradation inducers of porous particles, and combinations thereof. 
     
     
         3 . The method of  claim 2 , wherein the at least one active agent is a therapeutic agent. 
     
     
         4 . The method of  claim 1 , wherein the biodegradable polymer matrix comprises an unsaturated biodegradable polymer. 
     
     
         5 . The method of  claim 4 , wherein the biodegradable polymer comprises collagen, alginate, gelatin, polycaprolactone, poly(lactic-co-glycolic acid) (PLGA), poly(propylene fumarate)(PPP), poly(E-caprolactone-fumarate), or any combination thereof. 
     
     
         6 . The method of  claim 5 , wherein the biodegradable polymer comprises poly(propylene fumarate) (PPP). 
     
     
         7 . The method of  claim 1 , wherein the hydrogel porogen particles comprise poly(lactic-co-glycolic acid) (PLGA). 
     
     
         8 . The method of  claim 7 , wherein the hydrogel porogen particles further comprise at least one of alginates, fibrins, and gelatins. 
     
     
         9 . The method of  claim 1 , wherein the hydrogel porogen particles comprise at least one biocompatible vesicle. 
     
     
         10 . The method of  claim 9 , wherein the biocompatible vesicle comprises at least one of a liposome or a micelle. 
     
     
         11 . The method of  claim 1 , wherein the at least one biodegradable reinforcing particle comprises a silicon porous particle. 
     
     
         12 . The method of  claim 11 , wherein a surface of the biodegradable reinforcing particle is modified with a biodegradable polymer. 
     
     
         13 . The method of  claim 12 , wherein the biodegradable polymer is agarose, poly(lactic-co-glycolic acid) (PLGA), or a combination thereof. 
     
     
         14 . The method of  claim 11 , wherein the biodegradable reinforcing particle facilitates or controls at least one of intracellular delivery of an active agent, bio-distribution of an active agent, stability of an active agent, and internalization of the silicon porous particle by one or more cells or organelles. 
     
     
         15 . A method of providing an active agent to a patient, comprising: administering to a patient in need thereof, a composition that comprises:
 (a) a biodegradable polymer matrix comprising poly(propylene fumarate);   (b) a population of biodegradable reinforcing particles, dispersed within the biodegradable polymer matrix, and comprised of porous oxide particles, porous semiconductor particles, or a combination thereof;   (c) a population of hydrogel porogen particles dispersed within the biodegradable matrix, and comprised of poly(lactic-co-glycolic acid) (PLGA); and   (d) at least one active agent contained within the biodegradable polymer matrix, within the population of biodegradable reinforcing particles, within the population of hydrogel porogen particles, or any combination thereof.   
     
     
         16 . The method of  claim 15 , wherein the composition is formulated as an injectable. 
     
     
         17 . The method of  claim 15 , wherein the at least one active agent is selected from the group consisting of therapeutics, imaging agents, anti-inflammatory agents, antibiotics, proteins, platelet rich plasma, cells, stem cells, degradation inducers of porous particles, and combinations thereof. 
     
     
         18 . The method of  claim 17 , wherein the at least one active agent comprises a therapeutic. 
     
     
         19 . The method of  claim 15 , wherein a surface of the biodegradable reinforcing particles is modified with a biodegradable polymer. 
     
     
         20 . The method of  claim 19 , wherein the biodegradable polymer is agarose, poly(lactic-co-glycolic acid) (PLGA), or a combination thereof. 
     
     
         21 . The method of  claim 15 , wherein the biodegradable reinforcing particle facilitates or controls at least one of intracellular delivery of the active agent, bio-distribution of the active agent, stability of the active agent, and internalization of one or more of the biodegradable particles by one or more cells or organelles of the patient to which the composition is administered. 
     
     
         22 . The method of  claim 21 , wherein the biodegradable reinforcing particle comprises a degradation inducer of the population of hydrogel porogen particles. 
     
     
         23 . The method of  claim 22 , wherein the population of hydrogel porogen particles comprises alginate, and wherein the degradation inducer comprises sodium citrate. 
     
     
         24 . The method of  claim 15 , wherein the at least one biodegradable reinforcing particle comprises a mesoporous silica particle. 
     
     
         25 . The method of  claim 24 , wherein at least one imaging agent is embedded into a matrix of the mesoporous silica particle. 
     
     
         26 . The method of  claim 25 , wherein the at least one imaging agent comprises barium sulfate.

Join the waitlist — get patent alerts

Track US2019001025A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.